Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 5/20 | 0.37 |
| ▸ | KHK | P50053 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.32 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.32 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.32 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.32 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801299 | 0.84 | SMO (0.37) | SMOKHKEGFRHSD11B1CHI3L1 | |
| SCHEMBL30787812 | 0.82 | PDE10A (0.37) | HSD11B1 | |
| SCHEMBL20899099 | 0.82 | PDE10A (0.37) | HSD11B1 | |
| SCHEMBL25801194 | 0.80 | PDE10A (0.38) | — | |
| SCHEMBL25801258 | 0.79 | PDE10A (0.30) | — | |
| SCHEMBL25801282 | 0.78 | PDE10A (0.39) | EGFR | |
| SCHEMBL24151005 | 0.76 | JAK2 (0.35) | — | |
| SCHEMBL25801320 | 0.75 | FFAR1 (0.34) | — | |
| SCHEMBL30606276 | 0.75 | HRH4 (0.52) | SMO | |
| SCHEMBL21855839 | 0.75 | PDE10A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PTPN5, PTPN1, PTPN2 | SMO 287/4885KHK 3231/4885EGFR 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.